Review Article
Volume 13 Issue 11 - 2021
Deep Brain Stimulation - Breakthrough in Parkinson’s Disease Treatment
Srijamya1*, Prashant Upadhyay2, Muhammad Wasil Khan3, Jay Verma4 and Aayush2
1Faculty of Medicine, Ivane Javakhishvili Tbilisi State University, Tbilisi, Georgia
2Government Medical College, Jalaun, Uttar Pradesh, India
3Ziauddin Medical College, Pakistan
4Maulana Azad Medical College, India
*Corresponding Author: Srijamya, Faculty of Medicine, Ivane Javakhishvili Tbilisi State University, Tbilisi, Georgia.
Received: October 04, 2021; Published: October 27, 2021




Abstract

Importance: Deep Brain Stimulation [DBS] has been a breakthrough advancement in recent years in the treatment of Parkinson’s disease. The altercation still goes on the effectiveness of the unilateral and bilateral DBS but the patients in different stages of Parkinson’s disease have shown effective results with both unilateral and bilateral DBS.

Observations: Research and trials have shown the many beneficial outcomes of DBS in Parkinson's disease. These are pruning of motor fluctuation severity, a reduced daily dose of levodopa, and enhancement of sleep quality and cognitive functions. There are some disadvantages of DBS with the surgical procedure, implants, and their stimulation. These disadvantages can be conquered by advancements in the technology of DBS. The evolution in the DBS implants like connectivity of electrodes with automatic sensing technology, long battery life and connectivity with wifi can facilitate better outcomes of DBS in progressive neurodegenerative Parkinson's disease.

Conclusion: Motor symptoms of Parkinson’s disease and sleep quality have been seen to be improved with DBS. Negative symptoms like anhedonia, social withdrawal, etc. which are seen in patients with Parkinson’s disease do not show any reduction or improvement with DBS.

Keywords: Parkinson’s Disease (PD); Deep Brain Stimulation

References

  1. Olanow C Warren., et al. “Parkinson’s Disease and Other Movement Disorders”. Harrison’s Principles of Internal Medicine, edited by Dennis L. Kasper, Stephen L. Hauser, J. Larry Jameson, Anthony S. Fauci, Dan L. Longo, Joseph Loscalzo, McGraw Hill Education (2015): 2609.
  2. Krauss JK., et al. “Technology of deep brain stimulation: current status and future directions”. Nature Reviews Neurology2 (2021): 75-87.
  3. Stefani A., et al. “Mechanisms of action underlying the efficacy of deep brain stimulation of the subthalamic nucleus in Parkinson's disease: central role of disease severity”. European Journal of Neuroscience6 (2019): 805-816.
  4. Ashkan K., et al. “Insights into the mechanisms of deep brain stimulation”. Nature Reviews Neurology9 (2017): 548-554.
  5. Gardner J. “A history of deep brain stimulation: Technological innovation and the role of clinical assessment tools”. Social Studies of Science5 (2013): 707-728.
  6. Lozano AM., et al. “Deep brain stimulation: current challenges and future directions”. Nature Reviews Neurology3 (2019): 148-160.
  7. Alegret M., et al. “Effects of bilateral subthalamic stimulation on cognitive function in Parkinson disease”. Archives of Neurology8 (2001): 1223-1227.
  8. Tisch S., et al. “Pallidal stimulation modifies after-effects of paired associative stimulation on motor cortex excitability in primary generalised dystonia”. Experimental Neurology1 (2007): 80-85.
  9. Benabid AL., et al. “Deep brain stimulation of the subthalamic nucleus for Parkinson's disease: methodologic aspects and clinical criteria”. Neurology 12-6 (2000): S40-44.
  10. Deep-Brain Stimulation for Parkinson's Disease Study Group Obeso JA., et al. “Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease”. The New England Journal of Medicine 13 (2001): 956-963.
  11. Jahanshahi M., et al. “The impact of deep brain stimulation on executive function in Parkinson's disease”. Brain 6 (2000): 1142-1154.
  12. Ashby P and Rothwell JC. “Neurophysiologic aspects of deep brain stimulation”. Neurology12-6 (2000): S17-20.
  13. Brooks DJ and Samuel M. “The effects of surgical treatment of Parkinson's disease on brain function: PET findings”. Neurology12-6 (2000): S52-59.
  14. Deep-Brain Stimulation for Parkinson's Disease Study Group Obeso JA., et al. “Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease”. The New England Journal of Medicine13 (2001): 956-963.
  15. Odekerken VJ., et al. “Subthalamic nucleus versus globus pallidus bilateral deep brain stimulation for advanced Parkinson's disease (NSTAPS study): a randomised controlled trial”. The Lancet Neurology1 (2013): 37-44.
  16. Taba HA., et al. “A closer look at unilateral versus bilateral deep brain stimulation: results of the National Institutes of Health COMPARE cohort”. Journal of Neurosurgery6 (2010): 1224-1229.
  17. Bilateral deep brain stimulation (DBS) of the subthalamic nucleus (STN) or the globus pallidus interna (GPi) for treatment of advanced Parkinson's disease”. Tecnologica MAP (2001): 1-8.
  18. Okun MS. “Tips for Choosing a Deep Brain Stimulation Device”. JAMA Neurology7 (2019): 749-750.
  19. Bratsos S., et al. “Efficacy and Safety of Deep Brain Stimulation in the Treatment of Parkinson's Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials”. Cureus10 (2018): e3474.
  20. Perestelo-Pérez L., et al. “Deep brain stimulation in Parkinson's disease: meta-analysis of randomized controlled trials”. Journal of Neurology11 (2014): 2051-2060.
  21. Thevathasan W., et al. “Movement Disorders Society PPN DBS Working Group in collaboration with the World Society for Stereotactic and Functional Neurosurgery. Pedunculopontine nucleus deep brain stimulation in Parkinson's disease: A clinical review”. Movement Disorders1 (2018): 10-20.
  22. Odekerken VJ., et al. “Subthalamic nucleus versus globus pallidus bilateral deep brain stimulation for advanced Parkinson's disease (NSTAPS study): a randomised controlled trial”. The Lancet Neurology1 (2013): 37-44.
  23. Follett KA., et al. “CSP 468 Study Group. Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease”. The New England Journal of Medicine22 (2010): 2077-2091.
  24. Liu Y., et al. “Meta-analysis comparing deep brain stimulation of the globus pallidus and subthalamic nucleus to treat advanced Parkinson disease”. Journal of Neurosurgery3 (2014): 709-718.
  25. Xu H., et al. “Subthalamic nucleus and globus pallidus internus stimulation for the treatment of Parkinson's disease: A systematic review”. Journal of International Medical Research5 (2017): 1602-1612.
  26. Tan ZG., et al. “Efficacies of globus pallidus stimulation and subthalamic nucleus stimulation for advanced Parkinson's disease: a meta-analysis of randomized controlled trials”. Clinical Interventions in Aging 11 (2016): 777-786.
  27. Mao Z., et al. “Comparison of Efficacy of Deep Brain Stimulation of Different Targets in Parkinson's Disease: A Network Meta-Analysis”. Frontiers in Aging Neuroscience 11 (2019): 23.
  28. Okun MS and Foote KD. “Subthalamic nucleus vs globus pallidus interna deep brain stimulation, the rematch: will pallidal deep brain stimulation make a triumphant return?” Archives of Neurology4 (2005): 533-536.
  29. Liu Y., et al. “Subthalamic nucleus deep brain stimulation improves sleep in Parkinson's disease patients: a retrospective study and a meta-analysis”. Sleep Medicine 74 (2020): 301-306.
  30. Rizzone M., et al. “Deep brain stimulation of the subthalamic nucleus in Parkinson's disease: effects of variation in stimulation parameters”. Journal of Neurology, Neurosurgery, and Psychiatry2 (2001): 215-219.
  31. Dayal V., et al. “Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease: The Effect of Varying Stimulation Parameters”. The Journal of Parkinson's Disease2 (2017): 235-245.
  32. Reich MM., et al. “Short pulse width widens the therapeutic window of subthalamic neurostimulation”. Annals of Clinical and Translational Neurology4 (2015): 427-432.
  33. Wagle Shukla A and Okun MS. “Surgical treatment of Parkinson's disease: patients, targets, devices, and approaches”. Neurotherapeutics1 (2014): 47-59.
  34. Weaver FM., et al. “CSP 468 Study Group. Randomized trial of deep brain stimulation for Parkinson disease: thirty-six-month outcomes”. Neurology1 (2012): 55-65.
  35. Boel JA., et al. “NSTAPS study group. Cognitive and psychiatric outcome 3 years after globus pallidus pars interna or subthalamic nucleus deep brain stimulation for Parkinson's disease”. Parkinsonism and Related Disorders 33 (2016): 90-95.
  36. Unilateral vs. “Bilateral Subthalamic Stimulation in Parkinson's Disease (P1.168) Sara Duffus, Ugonma Chukwueke, Roy Strowd, Jennifer Green, Ihtsham Haq, Jessica Tate, Maja Herco, Adrian Laxton, Stephen Tatter, Mustafa Siddiqui Neurology 14 (2015):168.
  37. Lyons KE., et al. “Long term safety and efficacy of unilateral deep brain stimulation of the thalamus for parkinsonian tremor”. Journal of Neurology, Neurosurgery, and Psychiatry5 (2001): 682-684.
  38. Gardner J. “A history of deep brain stimulation: Technological innovation and the role of clinical assessment tools”. Social Studies of Science 5 (2013): 707-728.
  39. Chiken S and Nambu A. “Mechanism of Deep Brain Stimulation: Inhibition, Excitation, or Disruption?” Neuroscientist3 (2016): 313-322.
Citation: Srijamya., et al. “Deep Brain Stimulation - Breakthrough in Parkinson’s Disease Treatment”. EC Neurology 13.11 (2021): 15-25.

PubMed Indexed Article


EC Pharmacology and Toxicology
LC-UV-MS and MS/MS Characterize Glutathione Reactivity with Different Isomers (2,2' and 2,4' vs. 4,4') of Methylene Diphenyl-Diisocyanate.

PMID: 31143884 [PubMed]

PMCID: PMC6536005


EC Pharmacology and Toxicology
Alzheimer's Pathogenesis, Metal-Mediated Redox Stress, and Potential Nanotheranostics.

PMID: 31565701 [PubMed]

PMCID: PMC6764777


EC Neurology
Differences in Rate of Cognitive Decline and Caregiver Burden between Alzheimer's Disease and Vascular Dementia: a Retrospective Study.

PMID: 27747317 [PubMed]

PMCID: PMC5065347


EC Pharmacology and Toxicology
Will Blockchain Technology Transform Healthcare and Biomedical Sciences?

PMID: 31460519 [PubMed]

PMCID: PMC6711478


EC Pharmacology and Toxicology
Is it a Prime Time for AI-powered Virtual Drug Screening?

PMID: 30215059 [PubMed]

PMCID: PMC6133253


EC Psychology and Psychiatry
Analysis of Evidence for the Combination of Pro-dopamine Regulator (KB220PAM) and Naltrexone to Prevent Opioid Use Disorder Relapse.

PMID: 30417173 [PubMed]

PMCID: PMC6226033


EC Anaesthesia
Arrest Under Anesthesia - What was the Culprit? A Case Report.

PMID: 30264037 [PubMed]

PMCID: PMC6155992


EC Orthopaedics
Distraction Implantation. A New Technique in Total Joint Arthroplasty and Direct Skeletal Attachment.

PMID: 30198026 [PubMed]

PMCID: PMC6124505


EC Pulmonology and Respiratory Medicine
Prevalence and factors associated with self-reported chronic obstructive pulmonary disease among adults aged 40-79: the National Health and Nutrition Examination Survey (NHANES) 2007-2012.

PMID: 30294723 [PubMed]

PMCID: PMC6169793


EC Dental Science
Important Dental Fiber-Reinforced Composite Molding Compound Breakthroughs

PMID: 29285526 [PubMed]

PMCID: PMC5743211


EC Microbiology
Prevalence of Intestinal Parasites Among HIV Infected and HIV Uninfected Patients Treated at the 1o De Maio Health Centre in Maputo, Mozambique

PMID: 29911204 [PubMed]

PMCID: PMC5999047


EC Microbiology
Macrophages and the Viral Dissemination Super Highway

PMID: 26949751 [PubMed]

PMCID: PMC4774560


EC Microbiology
The Microbiome, Antibiotics, and Health of the Pediatric Population.

PMID: 27390782 [PubMed]

PMCID: PMC4933318


EC Microbiology
Reactive Oxygen Species in HIV Infection

PMID: 28580453 [PubMed]

PMCID: PMC5450819


EC Microbiology
A Review of the CD4 T Cell Contribution to Lung Infection, Inflammation and Repair with a Focus on Wheeze and Asthma in the Pediatric Population

PMID: 26280024 [PubMed]

PMCID: PMC4533840


EC Neurology
Identifying Key Symptoms Differentiating Myalgic Encephalomyelitis and Chronic Fatigue Syndrome from Multiple Sclerosis

PMID: 28066845 [PubMed]

PMCID: PMC5214344


EC Pharmacology and Toxicology
Paradigm Shift is the Normal State of Pharmacology

PMID: 28936490 [PubMed]

PMCID: PMC5604476


EC Neurology
Examining those Meeting IOM Criteria Versus IOM Plus Fibromyalgia

PMID: 28713879 [PubMed]

PMCID: PMC5510658


EC Neurology
Unilateral Frontosphenoid Craniosynostosis: Case Report and a Review of the Literature

PMID: 28133641 [PubMed]

PMCID: PMC5267489


EC Ophthalmology
OCT-Angiography for Non-Invasive Monitoring of Neuronal and Vascular Structure in Mouse Retina: Implication for Characterization of Retinal Neurovascular Coupling

PMID: 29333536 [PubMed]

PMCID: PMC5766278


EC Neurology
Longer Duration of Downslope Treadmill Walking Induces Depression of H-Reflexes Measured during Standing and Walking.

PMID: 31032493 [PubMed]

PMCID: PMC6483108


EC Microbiology
Onchocerciasis in Mozambique: An Unknown Condition for Health Professionals.

PMID: 30957099 [PubMed]

PMCID: PMC6448571


EC Nutrition
Food Insecurity among Households with and without Podoconiosis in East and West Gojjam, Ethiopia.

PMID: 30101228 [PubMed]

PMCID: PMC6086333


EC Ophthalmology
REVIEW. +2 to +3 D. Reading Glasses to Prevent Myopia.

PMID: 31080964 [PubMed]

PMCID: PMC6508883


EC Gynaecology
Biomechanical Mapping of the Female Pelvic Floor: Uterine Prolapse Versus Normal Conditions.

PMID: 31093608 [PubMed]

PMCID: PMC6513001


EC Dental Science
Fiber-Reinforced Composites: A Breakthrough in Practical Clinical Applications with Advanced Wear Resistance for Dental Materials.

PMID: 31552397 [PubMed]

PMCID: PMC6758937


EC Microbiology
Neurocysticercosis in Child Bearing Women: An Overlooked Condition in Mozambique and a Potentially Missed Diagnosis in Women Presenting with Eclampsia.

PMID: 31681909 [PubMed]

PMCID: PMC6824723


EC Microbiology
Molecular Detection of Leptospira spp. in Rodents Trapped in the Mozambique Island City, Nampula Province, Mozambique.

PMID: 31681910 [PubMed]

PMCID: PMC6824726


EC Neurology
Endoplasmic Reticulum-Mitochondrial Cross-Talk in Neurodegenerative and Eye Diseases.

PMID: 31528859 [PubMed]

PMCID: PMC6746603


EC Psychology and Psychiatry
Can Chronic Consumption of Caffeine by Increasing D2/D3 Receptors Offer Benefit to Carriers of the DRD2 A1 Allele in Cocaine Abuse?

PMID: 31276119 [PubMed]

PMCID: PMC6604646


EC Anaesthesia
Real Time Locating Systems and sustainability of Perioperative Efficiency of Anesthesiologists.

PMID: 31406965 [PubMed]

PMCID: PMC6690616


EC Pharmacology and Toxicology
A Pilot STEM Curriculum Designed to Teach High School Students Concepts in Biochemical Engineering and Pharmacology.

PMID: 31517314 [PubMed]

PMCID: PMC6741290


EC Pharmacology and Toxicology
Toxic Mechanisms Underlying Motor Activity Changes Induced by a Mixture of Lead, Arsenic and Manganese.

PMID: 31633124 [PubMed]

PMCID: PMC6800226


EC Neurology
Research Volunteers' Attitudes Toward Chronic Fatigue Syndrome and Myalgic Encephalomyelitis.

PMID: 29662969 [PubMed]

PMCID: PMC5898812


EC Pharmacology and Toxicology
Hyperbaric Oxygen Therapy for Alzheimer's Disease.

PMID: 30215058 [PubMed]

PMCID: PMC6133268


News and Events


May Issue Release

We always feel pleasure to share our updates with you all. Here, notifying you that we have successfully released the May issue of respective journals and the latest articles can be viewed on the current issue pages.

Submission Deadline for Upcoming Issue

ECronicon delightfully welcomes all the authors around the globe for effective collaboration with an article submission for the upcoming issue of respective journals. Submissions are accepted on/before May 25, 2022.

Certificate of Publication

ECronicon honors with a "Publication Certificate" to the corresponding author by including the names of co-authors as a token of appreciation for publishing the work with our respective journals.

Best Article of the Issue

Editors of respective journals will always be very much interested in electing one Best Article after each issue release. The authors of the selected article will be honored with a "Best Article of the Issue" certificate.

Certifying for Review

ECronicon certifies the Editors for their first review done towards the assigned article of the respective journals.

Latest Articles

The latest articles will be updated immediately on the articles in press page of the respective journals.